otcqx

Roche receives CE Mark for minimally invasive blood test to help rule out Alzheimers disease

Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer’s associated amyloid pathology.The minimally…

3 days ago

Enzon and Viskase Enter into Merger Agreement

Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined company June 20, 2025 20:16 ET…

1 month ago

ONWARD Medical Builds Commercial Momentum for the ARC-EX System and Reinforces its Brain-Computer Interface Leadership in Q1 2025

EINDHOVEN, the Netherlands, June 17, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading…

1 month ago

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients with Duchenne has been re-assessed,…

1 month ago

Orezone Announces Results of Meeting of Shareholders

VANCOUVER, British Columbia, June 13, 2025 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”)…

1 month ago

ONWARD Medical Announces Results of its Annual General Meeting of Shareholders

June 11, 2025 13:00 ET  | Source: ONWARD Medical NV THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF…

1 month ago

CITGO Sale Hearing Date Rescheduled to August 18, 2025

PEMBROKE, Bermuda--(BUSINESS WIRE)--Gold Reserve Ltd. (TSX.V: GRZ) (OTCQX: GDRZF) (“Gold Reserve” or the “Company”) announces that today the U.S. District…

2 months ago

Vireo Growth Inc. Announces Closing of Proper Brands Acquisition in Missouri

June 05, 2025 16:30 ET  | Source: Vireo Growth Inc. MINNEAPOLIS , June 05, 2025 (GLOBE NEWSWIRE) -- Vireo Growth…

2 months ago

Roches Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)

Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA Evrysdi offers…

2 months ago

New data show Roches Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced…

2 months ago